NT5E and neoplasm: Nevertheless, the improvement in PFS seen in patients with CD73-high tumour expression treated with FOLFOX and bevacizumab, with or without the addition of durvalumab and oleclumab, as compared to patients with CD73-low expression suggests the prognostic value of CD73.